Connect with us

Press Release

FormBlends Launches the Most Comprehensive GLP-1 and Peptide Intelligence Platform on the Internet, Featuring 7,282 Provider Profiles and 100 Clinical Research Reports

Published

2 months ago

on

San Francisco, CA, April 9th, 2026 – FormBlends, a health technology platform focused on GLP-1 weight loss results and weight management provider directory listings, today announced the completion of a major platform expansion that positions it as the most comprehensive consumer intelligence resource for prescription weight management medications in the United States. The platform now features 7,282 individually profiled provider listings across all 50 states, 100 physician-reviewed clinical research reports, 17 interactive health tools, and a clinical education library covering every major GLP-1 and peptide therapy on the market.

As the $45 billion GLP-1 market accelerates toward $122 billion by 2030, FormBlends is building the definitive consumer resource for evidence-based medication information, provider transparency, and clinical education.

FormBlends: Building the most comprehensive GLP-1 and peptide intelligence platform on the internet

The announcement comes as the global GLP-1 receptor agonist market reaches $45.3 billion in 2025, projected to hit $122.3 billion by 2030.

Goldman Sachs forecasts the anti-obesity drug market at $95 billion by 2030. J.P. Morgan projects the global incretin market at $200 billion by the same year. Morgan Stanley estimates $77 billion.

1 in 8 American Adults

are currently taking a GLP-1 medication, with an additional 14% expressing interest in starting treatment. Monthly prescriptions for GLP-1 receptor agonists have grown from 700,000 to 2.6 million since 2021.

An Information Crisis in the Fastest-Growing Drug Category

The explosive growth of GLP-1 receptor agonist therapies has created an equally explosive information gap. The National Consumers League documented a 1,200% increase in “violative or problematic” GLP-1-related advertising between 2022 and 2024. Separately, the National Association of Boards of Pharmacy found that approximately 95% of websites offering prescription-only medications online operate outside of legal requirements, with 96% not requiring a valid prescription.

Harvard Medical School researchers have flagged social media as a primary vector for GLP-1 misinformation, with platforms like TikTok rampant with false claims about supplements and foods that supposedly replicate the effects of prescription medications. The FDA has issued multiple warnings about fraudulent products with false labeling entering the market.

“Patients are navigating an information environment where marketing is frequently disguised as medical advice,” said a FormBlends spokesperson. “The gap between what consumers need to know and what they can reliably find online is widening every month. We built this platform to close that gap with physician-reviewed, evidence-based clinical content.”

“We are not building a company that happens to have health content. We are building the most trusted clinical resource on the internet for GLP-1 and peptide therapy information, backed by peer-reviewed research and transparent provider data.”

What FormBlends Has Built: A Platform Overview

  1. The National Provider Directory. FormBlends now maintains 7,282 individually profiled weight management clinic listings across all 50 states, each featuring verified ratings, treatment offerings, pricing transparency data, patient review analysis, and an editorially written assessment. Unlike aggregator sites that scrape listings without context, every FormBlends profile includes editorial content reviewed by the platform’s medical team, honest advantages and limitations, and transparent cost comparison information. Provider data is sourced from the Yelp Fusion API and verified quarterly.
  2. Clinical Research Library. The platform’s research section houses 100 physician-reviewed reports covering GLP-1 receptor agonists, peptide therapies, and weight management science. Each report cites peer-reviewed sources from journals including the New England Journal of Medicine, JAMA, The Lancet, and Nature Medicine. FormBlends’ ambition is to function as the most complete reference library for GLP-1 and peptide clinical data on the internet, organized and explained for patients rather than clinicians.
  3. Interactive Health Tools. FormBlends offers 17 free clinical tools including a BMI calculator, drug interaction checker, insurance coverage checker, dosing schedule planner, peptide dosage calculator, and weight loss timeline estimator. These tools are designed to help patients prepare for conversations with their physicians, not replace medical consultation.
  4. Educational Article Library. The platform’s clinical education library includes comprehensive guides organized by drug class and therapeutic category. Article hubs cover GLP-1 receptor agonists, peptide therapy, medication comparisons, side effect profiles, dosing protocols, and cost analyses. Every article is medically reviewed and updated quarterly with current clinical data. All clinical claims cite peer-reviewed sources.

The Clinical Evidence: Why GLP-1 Medications Are Reshaping Medicine

The scale of FormBlends’ investment in clinical education reflects the extraordinary scope of what published research shows GLP-1 receptor agonists are capable of. These medications have demonstrated benefits extending well beyond weight management into cardiovascular disease, kidney disease, and metabolic health, representing what many researchers describe as the most significant pharmacological development in endocrinology in decades.

Clinical Trial Published Finding Source
STEP 1-4 14.9%-17.4% mean body weight loss at 68 weeks; 69-79% of patients achieved clinically meaningful weight reduction              NEJM, 2021
STEP 5 (Long-term) 16.7% sustained weight reduction maintained at 104 weeks vs. 0.6% with placebo Nature Medicine, 2022
SURMOUNT-1 22.5% weight reduction at highest dose; 63% of participants achieved 20% or greater reduction NEJM, 2022
SURMOUNT-5 (Head-to-Head)         Tirzepatide 20.2% vs. semaglutide 13.7% weight reduction at 72 weeks Applied Clinical Trials, 2025
SELECT (Cardiovascular) 20% reduction in major adverse cardiovascular events across 17,604 patients (HR 0.80) NEJM, 2023
FLOW (Kidney) 24% reduction in composite kidney endpoint; trial stopped early due to efficacy ADA, 2024

 

FormBlends’ research library provides detailed breakdowns of each of these trials, including a comprehensive semaglutide vs tirzepatide comparison, all translated from clinical language into patient-accessible explanations. The platform’s goal is to make published clinical data as accessible as possible, so patients can have informed conversations with their physicians about whether these therapies may be appropriate for their individual circumstances.

A $1.4 Trillion Problem

The economic burden of obesity in the United States is staggering. The Milken Institute and the GWU STOP Obesity Alliance estimate the total economic impact at $1.4 trillion annually when accounting for direct medical expenses and lost productivity.

Adults with obesity incur an average of $2,505 more in annual medical costs than normal-weight adults, with costs escalating to 233.6% higher for individuals with Class 3 obesity. US prescription drug spending hit $805.9 billion in 2024, up 10.2% year-over-year, with weight management medications accounting for 46.8% of the total increase.

Total US spending on GLP-1 receptor agonists grew over 500% from $13.7 billion in 2018 to $71.7 billion in 2023, according to a study published in JAMA Network Open.

$71.7 Billion

Total US GLP-1 receptor agonist spending in 2023, up from $13.7 billion in 2018. Weight management medications drove 46.8% of all US prescription drug spending growth in 2024.

Medicare Coverage: A Catalyst for Information Demand

Beginning July 1, 2026, Medicare will cover select GLP-1 receptor agonist medications for weight management at a $50 per month copay through the new “Medicare GLP-1 Bridge” program, marking the first-ever Medicare coverage for obesity medications after a two-decade exclusion. The CMS BALANCE Model, launching January 2027 for Medicare Part D, is projected to further expand access.

Goldman Sachs projects 15 million US adults will be on anti-obesity medications by 2030, representing 13% of the adult population excluding those with diabetes. J.P. Morgan’s estimate is higher: 25 million Americans by the same year.

“Medicare coverage will bring tens of millions of new patients into this category for the first time,” said a FormBlends spokesperson. “These patients will need reliable, physician-reviewed information to make informed decisions. That is exactly what our clinical resources and research library are designed to provide. We want to be the place physicians recommend their patients go to learn.”

The Peptide Frontier: Education Beyond GLP-1

FormBlends’ platform extends beyond GLP-1 receptor agonists into the broader peptide therapy landscape, which reached $140.86 billion globally in 2025 and is projected to grow to $260.25 billion by 2030 at a 10.77% CAGR.

The platform’s peptide education resources, dosage calculators, and reconstitution reference tools serve a growing consumer segment seeking evidence-based information about therapies gaining attention in longevity and regenerative medicine research. The platform’s retatrutide research hub covers next-generation triple-agonist GLP-1 therapies currently in late-stage clinical trials.

The Search for Answers: Consumer Behavior Signals Demand for Better Resources

Consumer search behavior reflects the intensity of demand for reliable GLP-1 information. The term “GLP-1” now averages over 3 million monthly Google searches, having surpassed “Ozempic” in search volume by early 2025 as consumers shift from brand-name awareness to drug-class research.

A longitudinal analysis published in PMC found that prescription volume and search volume for GLP-1 medications are correlated at r = 0.97, one of the highest correlation coefficients ever recorded between prescription drug utilization and online search behavior. This suggests that patients are actively researching these medications before and during treatment.

This behavioral shift signals a more sophisticated patient population, one that is no longer searching for a brand name from a television commercial but actively comparing clinical evidence, evaluating providers, and assessing costs before making treatment decisions. FormBlends’ provider comparison tools, head-to-head treatment analyses, and ranked provider guides are built specifically for this informed patient.

A New Face of Wellness

FormBlends’ thesis is that the GLP-1 era represents a fundamental shift in how Americans relate to their own health. For the first time, millions of people who were told that weight management was purely a matter of willpower have access to medications that address underlying biological mechanisms, medications backed by the largest, most rigorous clinical trial programs in modern endocrinology.

The company’s content philosophy reflects this shift. FormBlends does not position itself as a marketing platform. It provides clinical information, transparent provider data, and educational resources that allow patients to make decisions grounded in evidence rather than advertising. Every page on the platform, from the side effects guides to the provider directory to the health assessment, is reviewed by licensed clinicians and updated with current published data.

“For decades, the wellness industry sold aspiration. We are building something different: a platform that provides clarity. Patients deserve to know what these medications do, what the published clinical evidence shows, and where to find a qualified provider. If we do that well, the rest takes care of itself.”

“The consumer searching for GLP-1 information in 2026 is fundamentally different from the consumer who first typed ‘Ozempic’ into Google in 2023,” said a FormBlends spokesperson. “They are researching drug classes, reading published trial data, and comparing provider credentials before scheduling consultations. We built this entire platform for that patient.”

By the Numbers: FormBlends Platform as of April 2026

Platform Metric Value
Provider profiles maintained                               7,282 across all 50 states + D.C.
Clinical research reports 100 physician-reviewed
Interactive health tools 17 (free, no account required)
Educational articles 200+ medically reviewed guides
Drug classes covered GLP-1 receptor agonists, peptides, TRT
FAQs answered 72,820+ across directory and articles
Medical review process All content reviewed by licensed clinicians
Content update cycle Quarterly with latest published clinical data
Provider data source Yelp Fusion API, verified quarterly
Health assessment Free 2-minute online assessment


Availability

The FormBlends platform is available now at formblends.com. All educational content, research reports, interactive tools, and provider directory listings are free to access. Patients interested in exploring whether physician-supervised treatment may be appropriate for their circumstances can begin with a free health assessment.

About FormBlends

FormBlends is a health technology platform focused on GLP-1 receptor agonist education, peptide therapy research, and clinical health information. The platform combines the largest independently maintained weight management provider directory in the United States with interactive health tools, a peer-reviewed clinical research library, and physician-supervised telehealth consultations. All medical content is reviewed by licensed clinicians. Learn more at formblends.com.

Important Disclosures: This press release is for informational purposes only and does not constitute medical advice. GLP-1 receptor agonist medications are prescription treatments that require evaluation by a licensed healthcare provider. Clinical trial results cited in this release refer to published, peer-reviewed studies of FDA-approved branded medications and may not be representative of outcomes with any other products. Individual results vary. Always consult a qualified healthcare professional before starting any prescription treatment. The FormBlends provider directory is an informational resource; inclusion does not constitute endorsement. Provider data is sourced from publicly available information and verified quarterly.

Media Contact

FormBlends Communications

Team@formblends.com

formblends.com/about

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Related Topics:
Continue Reading

Press Release

Loox launches Reviewers.com, the first product sampling platform built exclusively for Shopify brands

Published

1 hour ago

on

June 17, 2026

By

Tel Aviv, Israel, June 17th, 2026, FinanceWire

After a decade as the social proof leader trusted by 130,000 Shopify brands, Loox announces the public launch of Reviewers.com, a product sampling platform in the Shopify App Store that helps Shopify brands get high-quality video reviews at scale from a vetted community of everyday consumers. 

Why It Matters 

Consumer trust has never been lower due to the increase in synthetic content – AI-generated copy, fake reviews, and manufactured influencer content. Trust in brands is at an all-time low, and authentic social proof has never mattered more. Visual reviews build trust and convert browsers into buyers; they convert more than textual or photo reviews – but getting them in a consistent, scalable way has always been painfully hard. Not every customer has the setup, motivation, or time to record a high-quality video. Reviewers.com changes that. 

How It Works 

Reviewers.com connects Shopify brands with real, everyday consumers who are strictly screened for clear audio, good lighting, and on-camera presence before they can enter the community. It’s a predictable, scalable way to get high-quality, authentic video reviews on demand. Brands gift their products; reviewers post honest, authentic video reviews in return. Reviewers.com saves brands hundreds of hours spent on finding creators, coordinating shipping, and validating their content. Campaigns are created in just a few minutes, fully integrated into Shopify, and every review comes with full usage rights.

“The campaign was very easy to set up, the reviews came in quickly, and there were really good, thoughtful reviews,” said Nana Adwoa Denkyiraa, founder of Ayebea’s Sankofa Marketplace. 

Key use cases 

  • Creating a steady stream of fresh video content for marketing and ads 
  • Seeding social proof for new product launches 
  • Keeping review widgets on product pages fresh and compelling 
  • Capturing seasonal content throughout the year 
  • Showcasing reviews from consumers who mirror the brand’s target audience

From the CEO 

“After 10 years helping Shopify brands collect and display social proof, we kept seeing the same problem: brands know video reviews are the strongest way to build trust with visitors and turn browsers into buyers, but they have no reliable way to get them. Reviewers.com solves that – authentically, affordably, and at scale,” said Yoni Elbaz, CEO and Co-founder of Loox. 

How is it different 

Unlike Influencer and UGC Platforms, Reviewers.com is purpose-built for honest product reviews – not polished influencer content or scripted UGC. Reviewers.com helps brands collect more compelling content by delivering reviews that are: 

  • FTC compliant – transparently disclosed, no grey areas 
  • Authentic and unscripted – real people sharing honest opinions 
  • High-quality – reviewers are screened before joining, and each review submitted is screened for audio, lighting, and content. 
  • Fully licensed – brands receive complete usage rights to every video. 

Who are the Reviewers, and how are they vetted 

Reviewers are real, everyday consumers who love trying new products and sharing honest opinions. Every Reviewer in our community is carefully vetted. Before participating, each candidate submits a sample video that we personally review for authenticity, fluent English, clear sound, and good lighting. Only those who meet our high standards are approved as Reviewers. As they join campaigns, we apply the same criteria to every video they submit, ensuring quality is maintained and continually improved. 

Availability and Pricing 

Reviewers.com is available today in the Shopify App Store to any US-based Shopify brand. Pricing is based on a monthly subscription with no long-term commitment. The monthly subscription is $150, including one campaign, with additional campaigns available for $150 per campaign. Each campaign can include up to 10 items gifted. Each merchant receives a 30-day free trial, which includes one free campaign. 

Readers can visit Reviewers.com to learn more and to start your first campaign free.

Resources 

About Loox 

Loox is the leading social proof platform for Shopify brands, trusted by more than 130,000 brands worldwide. For over 10 years, Loox has helped merchants collect, display, and leverage customer reviews and photos to build trust and drive sales. 

About Reviewers.com 

Reviewers.com helps brands collect authentic, high-quality video reviews through a trusted community of vetted reviewers who are excited to try products for free in exchange for sharing their honest review. Launching a campaign takes just minutes. Simply create your campaign, gift your products, and we handle the rest – from matching you with the right reviewers who place their orders directly through your website. Within weeks, you’ll receive high-quality video reviews with full usage rights, ready to use across your marketing channels, social ads, email campaigns, landing pages, and product review widgets. Whether you’re launching a new product, targeting a new audience, preparing for a seasonal campaign, or refreshing your brand content, Reviewers.com gives you authentic video reviews tailored to every marketing need.

Contact

Chief Business Officer
Natasha Shine-Zirkel
Reviewers.com
merchant-support@reviewers.com

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Mita TechTalks Convenes 125 Investors and Builders in Punta Mita for an Invite-Only Summit on Bitcoin, AI, and Energy

Published

1 hour ago

on

June 17, 2026

By

Punta Mita, Mexico, June 16th, 2026, FinanceWire

Running October 25–27, the summit pairs beachfront sessions and private villa workshops built to turn three days of conversation into strategies attendees can act on.

Mita TechTalks, an invite-only summit on the convergence of Bitcoin, artificial intelligence, and energy, will gather 125 guests October 25–27, 2026, in Punta Mita, Mexico. The summit brings together high-net-worth investors, family office allocators, corporate leaders, and builders for three days of oceanside sessions, private workshops, and unhurried conversations along the most exclusive stretch of Mexico’s Pacific coast. 

Sessions take place at the Kupuri Beach Club, an oceanview, open-air venue inside the private, residential community of Punta Mita, home to the Four Seasons, St. Regis, Montage, and Pendry resorts and two Jack Nicklaus Signature golf courses. The agenda opens with a beachfront welcome dinner, followed by full sessions and private-villa breakout workshops, evening dinners under the palapa, and a closing afternoon of Jack Nicklaus Signature golf or ocean sports. Because guests and speakers stay within the same community for the full three days, the schedule gives way to long, off-record conversations, and the chance to build authentic relationships with the people rather than collect badges.

Confirmed speakers include Jeff Booth, founder of ego death capital and author of The Price of Tomorrow; Lisa Hough, founder of BTM Energy; Sam Callahan, Director of Strategy and Research at OranjeBTC; Andre Neves, ZBD Co-Founder & CTO and more. Additional speakers will be announced in the coming weeks.

The summit is built on a simple premise: Bitcoin, artificial intelligence, and energy are no longer separate stories. Bitcoin is moving onto corporate balance sheets and into treasury strategy, AI is working its way into finance and the Bitcoin economy, and the power demands of both AI data centers and Bitcoin mining are redrawing the energy map. Programming spans three tracks, covering macro and corporate strategy, energy, and AI, where speakers and guests dig into how the three feed one another.

“Technology is inherently deflationary, and AI is about to accelerate that beyond anything we’ve seen. The real question for investors and companies is how you position for a world where the cost of almost everything trends toward zero,” said Jeff Booth, founder of ego death capital and author of The Price of Tomorrow. “In a fast paced world, the most meaningful breakthroughs happen when you slow down. That’s what Mita TechTalks is built for, and it’s why Bitcoin, AI, and energy belong in the same room, in a place like Punta Mita.”

Mita TechTalks is organized by Lynne Bairstow and Israel Muñoz, partners at Base Layer Advisors and co-hosts of the Build With Bitcoin podcast. Bairstow began her career on Wall Street at Merrill Lynch before moving to Mexico, where she founded MITA Ventures in 2012 and has spent more than two decades backing early-stage tech across Mexico and Latin America; she is also a co-founder of La Casa de Satoshi, a Bitcoin and freedom-tech hub in Mexico City. Muñoz co-founded an early cross-border payments startup and helped launch 500 Startups’ Miami operation, and now invests in early-stage Bitcoin infrastructure ventures.

“Some of the best moments at these gatherings happen away from the sessions. They happen at dinner, walking the beach, in a villa after the sessions end,” said Bairstow. “When a small group of people share the same place for three days, you leave having actually gotten to know the people at the forefront of capital market innovation.”

“Bitcoin, AI, and energy are the technologies that will redefine the global economy,” said Muñoz. “We wanted to bring the people at the center of that shift together somewhere they could actually talk, and there’s no better place to do it than in Punta Mita.”

Registration is open by application at 2026.mitatechtalks.com. Passes are released in tiers starting at $2,750 and rising as each phase sells out, and the summit is capped at 125 guests; once that number is reached, registration closes. Every pass includes full access to sessions and workshops, all meals, and evening events. Punta Mita is located 40 minutes from Puerto Vallarta International Airport.

This year’s Mita TechTalks is supported by ArcadiaB as Platinum Partner and Punta Mita as Host Partner, with Base Layer Advisors and Build With Bitcoin as Organizing Partners and Forager and Gannett Trust as Bronze Sponsors. If you are interested in sponsoring, please contact lynne@baselayeradvisors.com. 

About Mita TechTalks 

Mita TechTalks is an invite-only summit exploring the intersection of capital markets, Bitcoin, artificial intelligence, and energy. Held in the private, gated community of Punta Mita on Mexico’s Pacific coast, it is designed for wealth managers, family offices, corporate executives, and industry leaders shaping the future of capital. Organized by Base Layer Advisors and Build With Bitcoin, the summit returns October 25–27, 2026. For more information, users can visit 2026.mitatechtalks.com.

Contact

Founder
Phil
21M Communications
phil@21mcommunications.com

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Nocera Strengthens AI Growth Strategy with Strategic Investment in CampaignPulse.ai

Published

1 hour ago

on

June 17, 2026

By

Englewood Cliffs, NJ, June 16th, 2026, FinanceWire

Nocera, Inc. (NASDAQ:NCRA) has taken another significant step in its transformation into a diversified technology holding company by announcing a strategic investment in CampaignPulse.ai, an emerging artificial intelligence company focused on simulation-driven campaign intelligence, predictive analytics, and decision-support technologies.

The investment underscores Nocera’s commitment to building a portfolio of innovative businesses positioned at the forefront of artificial intelligence and digital transformation. As organizations across industries increasingly seek data-driven tools to improve planning, communication, and operational effectiveness, CampaignPulse.ai is developing solutions designed to help users evaluate strategies before committing valuable resources in real-world environments.

Expanding Nocera’s AI Ecosystem

The investment aligns with Nocera’s broader vision of evolving into Nocera Holdings, a technology-focused platform targeting high-growth sectors including artificial intelligence, digital infrastructure, robotics, biotech, blockchain, and digital assets.

By adding CampaignPulse.ai to its growing portfolio, Nocera gains exposure to a rapidly emerging segment of the AI market focused on predictive analytics, audience intelligence, and advanced simulation technologies. These capabilities are increasingly viewed as essential tools for organizations seeking to make faster, smarter, and more informed decisions.

“Our investment in CampaignPulse.ai represents another important step in the execution of Nocera’s strategy to build a diversified portfolio of technology-driven businesses operating in high-growth markets,” said Andy Jin, Chief Executive Officer of Nocera.

Building the Future of Campaign Intelligence

CampaignPulse.ai is developing an innovative platform designed to leverage large language models and artificial intelligence to simulate audience reactions, test messaging effectiveness, and evaluate strategic outcomes before implementation.

The platform’s planned capabilities include:

  • AI-powered campaign simulations
  • Predictive audience intelligence
  • Message testing and optimization
  • Sentiment and narrative analysis
  • Strategic communications support
  • Reputation monitoring
  • Performance analytics and reporting
  • Content creation and campaign development tools
  • Localization and personalization technologies

By combining advanced AI with predictive modeling, CampaignPulse.ai aims to help organizations reduce uncertainty, improve communication effectiveness, and optimize resource allocation.

Addressing a Growing Market Opportunity

The global demand for AI-powered analytics and decision-support solutions continues to expand as businesses, governments, advocacy groups, and institutions seek more sophisticated ways to forecast outcomes and improve strategic planning.

Nocera believes that technologies capable of integrating simulation, predictive analytics, and audience intelligence will play an increasingly important role in helping organizations navigate complex decision-making environments.

CampaignPulse.ai’s development roadmap also includes the creation of a global ambassador network intended to accelerate market awareness, foster strategic partnerships, and support future platform adoption across international markets.

Long-Term Vision for Shareholder Value

The investment reflects Nocera’s ongoing strategy of identifying innovative companies that can benefit from the accelerating adoption of artificial intelligence. Through a combination of strategic investments, acquisitions, and partnerships, the company aims to build a scalable portfolio of technology businesses capable of delivering sustainable long-term growth.

“We are excited to welcome Nocera as a strategic investor and partner,” said Ash Wright, President of CampaignPulse.ai. “We believe the combination of AI-powered simulations, predictive analytics, and decision-support capabilities can create a powerful new approach to campaign intelligence and strategic communications.”

As Nocera continues its transformation into a diversified technology platform, investments such as CampaignPulse.ai demonstrate the company’s focus on emerging technologies that have the potential to reshape industries, improve efficiency, and create meaningful value for shareholders and stakeholders alike.

With artificial intelligence rapidly becoming a cornerstone of modern business strategy, Nocera’s latest investment positions the company to participate in one of the most dynamic and transformative sectors of the global economy.

For more information visit – https://www.nocera.company/

Contact

Public Relations
Jackson Phoenix
Phoenix MGMT & Consulting Group
PR@PhoenixMGMTConsulting.com

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

LATEST POST

Like Us
Follow Us
Subscribe Us
Follow Us